XML 45 R29.htm IDEA: XBRL DOCUMENT v3.21.2

Revenues - Revenues Disaggregated by Significant Customer (Details) - Customer Concentration Risk	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 02, 2021	Jul. 03, 2020	Jul. 02, 2021	Jul. 03, 2020	Jan. 01, 2021
Ipsen Pharma SAS | Revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues	24.00%	20.00%	19.00%	17.00%
Ipsen Pharma SAS | Accounts Receivable
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues			24.00%		23.00%
Affiliates of McKesson Corporation | Revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues	14.00%	11.00%	14.00%	13.00%
Affiliates of McKesson Corporation | Accounts Receivable
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues			21.00%		12.00%
Affiliates of CVS Health Corporation | Revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues	13.00%	13.00%	14.00%	15.00%
Affiliates of CVS Health Corporation | Accounts Receivable
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues			13.00%		11.00%
Affiliates of AmerisourceBergen Corporation | Revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues	12.00%	11.00%	13.00%	11.00%
Affiliates of AmerisourceBergen Corporation | Accounts Receivable
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues			19.00%		11.00%
Affiliates of Optum Specialty Pharmacy | Revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues	8.00%	10.00%	9.00%	11.00%
Accredo Health, Incorporated | Revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues	8.00%	10.00%	8.00%	9.00%
Takeda Pharmaceutical Company Limited | Revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues	2.00%	10.00%	2.00%	5.00%
Takeda Pharmaceutical Company Limited | Accounts Receivable
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Percent of total revenues			4.00%		10.00%

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_MajorCustomersAxis=exel_IpsenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=exel_TakedaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: